Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

JAMA

Volumn 286, Issue 20, 2001, Pages 2568-2577

  Hogg, Robert S ^a,b   Yip, Benita ^a   Chan, Keith J ^a   Wood, Evan ^a,c   Craib, Kevin J P ^a   O'Shaughnessy, Michael V ^a,b   Montaner, Julio S G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CAUSE OF DEATH; CELL COUNT; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0035965633     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.20.2568     Document Type: Article

References (31)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
3. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV infected patients
4. Anti-retroviral therapy in adults
5. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
6. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
7. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter
8. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
9. Plasma viral load and CD4+lymphocytes as prognostic markers of HIV-1 infection
10. Viral load changes in response to antiretroviral therapy according to the baseline CD4 lymphocyte count and viral load
11. When to start HAART in chronically HIV-infected patients?
12. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
13. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
14. Antiretroviral therapy for HIV infection in 1996
15. Antiretroviral therapy for HIV infection in 1997
16. Acquired immune deficiency syndrome (AIDS): Interim proposal for a WHO staging system for HIV infection and disease
17. Regression models and life tables
18. Trends in survival of Danish AIDS patients from 1981 to 1989
19. Survival trends for patients with AIDS
20. Factors influencing survival after AIDS
21. The predictive value of T cell function in vitro and pre-AIDS zidovudine use for survival after AIDS diagnosis in a cohort of homosexual men in Amsterdam
22. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
23. Changes in plasma HIV-1 RNA and CD4+lymphocyte counts and the risk of progression to AIDS
24. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion
25. Nonadherence to triple combination therapy is predictive of AIDS progression and death in HIV-positive men and women
26. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997
27. Long-term survival after initiation of antiretroviral therapy
28. CD4+lymphocyte level is better than HIV-1 plasma viral load in determining when to initiate HAART
29. Late initiation of antiretroviral therapy (at CD4+lymphocyte count <200 cells/mL) is associated with increased risk of death